Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Correlation of peak lymphocyte count after axi-cel and clinical response in lymphoma

Yi Lin • 6 Dec 2019
ASH 2019
B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Axicabtagene ciloleucel CAR-T

Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses how the peak expansion of absolute lymphocyte count after CAR-T infusion is a clinically accessible test that correlates with clinical response in axicabtagene ciloleucel therapy for lymphoma. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Yi Lin

1:59
Factors to consider when choosing between cilta-cel and ide-cel for R/R multiple myeloma
Yi Lin • 9 Dec 2023
1:50
Real-world outcomes of teclistamab treatment in R/R multiple myeloma
Yi Lin • 9 Dec 2023
1:32
AEs associated with CAR-T in patients with triple-class exposed R/R MM: analysis from KarMMa-3
Yi Lin • 9 Dec 2023
3:04
Outpatient monitoring following CAR-T and BsAb treatment for patients with lymphoma and MM
Yi Lin • 9 Dec 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals